ONCAlert | 2017 San Antonio Breast Cancer Symposium

Results for Pembrolizumab as a First-Line Therapy for Advanced Urothelial Carcinoma

Arjun Balar, MD
Published Online:10:17 AM, Mon May 22, 2017

Arjun Balar, MD, assistant professor, Department of Medicine, and director, Genitourinary Medical Oncology Program, NYU Langone Medical Center, discussed results of the KEYNOTE-052 study of pembrolizumab (Keytruda) as a first-line therapy for patients with cisplatin-ineligible advanced urothelial cancer.
Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.